Featured Research

from universities, journals, and other organizations

Smallpox Vaccine Alternative Identified

Date:
January 9, 2008
Source:
University of California - Irvine
Summary:
Infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus. Scientists applied blood serum samples taken from both humans and animals given the MVA or Dryvax vaccines to "microarray" chips containing more than 200 vaccinia virus proteins, on which they simultaneously studied how the serum antibodies responded to all the vaccinia proteins.

Smallpox chip with dime.
Credit: Image courtesy of University of California - Irvine

University of California, Irvine infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus.

Related Articles


Philip Felgner and Huw Davies with the Department of Medicine found that the modified vaccinia virus Ankara (MVA) produced the same antiviral response in human and animal studies as the current smallpox vaccine, Dryvax. The study is part of a national effort to develop a replacement for the Dryvax vaccine, which causes serious complications in some people.

“Studies have shown MVA to be a much safer vaccine product that takes advantage of modern technology,” Felgner said. “We are pleased that our advanced analytical methods may help to bring an effective and safer vaccine to the public.”

Smallpox was declared eradicated worldwide in 1980; the last naturally occurring case in the world was in Somalia in 1977. Routine vaccination against smallpox in the U.S. stopped in 1972, and Dryvax production was halted in 1982.

Both Dryvax and MVA are strains of vaccinia virus, which is related to the smallpox virus. The antibodies created by vaccinia virus infection protect a person against a lethal smallpox infection, making it suitable for use as a vaccine. Unlike smallpox virus, vaccinia creates a very mild infection and is completely safe for healthy individuals.

Although Dryvax was effective during the eradication campaign in the 1960s and ’70s, its manufacturing methods are outdated by today’s standards, and it is also associated with significant risk of adverse reactions for immune-compromised individuals.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, identified MVA as a possible candidate to replace Dryvax. MVA was first developed in the 1970s and has been administered to animal species and humans with little or no adverse side effects.

In the study, Felgner and Davies applied blood serum samples taken from both humans and animals given the MVA or Dryvax vaccines to “microarray” chips containing more than 200 vaccinia virus proteins, on which they simultaneously studied how the serum antibodies responded to all the vaccinia proteins.

The researchers found that these antibody responses were similar in both the animal and human subjects regardless whether they were given MVA or Dryvax, suggesting that MVA contains antiviral properties similar to those in Dryvax.

This similarity is vital, Davies says, because if a vaccine initiates an immune response in humans that matches the one in animals that are protected against lethal pox viruses, then public health officials will have more confidence that the vaccine will be effective in humans.

“This is particularly important for vaccines against lethal infections like smallpox, where human clinical trials cannot be done,” he added.

The study marked a collaboration between UC Irvine and ImmPORT Therapeutics Inc. in Irvine, who manufacture the arrays. The animal tests were done by the NIAID, and human studies were held at Saint Louis University. The NIH supported the study.

UC Irvine is home to the Pacific-Southwest Center for Biodefense and Emerging Infectious Diseases Research – one of only 10 federally funded regional centers dedicated to research for countering bioterrorism and infectious disease threats.

About the protein microarray laboratory

The protein microarray laboratory at UC Irvine and ImmPORT has developed an efficient method for producing all of the proteins from infectious agents like smallpox and printing them onto microarray chips. The chips can be probed with serum from vaccinated individuals to study the antibodies that are produced after vaccination or infection. The team has produced and printed microarray chips containing 16,000 different proteins from 20 infectious agents, including the organisms responsible for tuberculosis and malaria.

Full results are published in the Journal of Virology.


Story Source:

The above story is based on materials provided by University of California - Irvine. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Irvine. "Smallpox Vaccine Alternative Identified." ScienceDaily. ScienceDaily, 9 January 2008. <www.sciencedaily.com/releases/2008/01/080107090951.htm>.
University of California - Irvine. (2008, January 9). Smallpox Vaccine Alternative Identified. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2008/01/080107090951.htm
University of California - Irvine. "Smallpox Vaccine Alternative Identified." ScienceDaily. www.sciencedaily.com/releases/2008/01/080107090951.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins